Ruowen (Jeffrey) Zhang, Ph.D., M.D.
Ruowen Zhang, Ph.D., M.D., earned his M.D. in Forensic Medicine at West China Medical Center of Sichuan University, China in 2007. He then earned his Ph.D. in Biochemistry at Queen’s University of Belfast, UK in December 2011. While a Doctoral student, he identified twelve novel bioactive peptides from frog and toad skin samples by molecular biology technology, and optimized protocols for protein expression in bacterium using the pET system. He next joined Shenyang Sunshine Pharmaceutical Co., LTD, China, as a R&D Scientist between 2011 and 2012. He next spent one year as a Visiting Scholar at Nelson Institute of Environmental Medicine, at New York University School of Medicine until October 2013. After which, he spent another year as Visiting Scholar in the Department of Pathology at the University of North Dakota. In December of 2014, he joined the University of Alabama at Birmingham as a post-doctoral researcher to study the mechanism of cell reprogramming, investigate epigenetic regulation to maintain pluripotency and self-renewal in human pluripotent stem cells, seek out enhancers or barriers which regulate iPSC generation, and investigate the function of cell cycle in the reprogramming process. In 2016, he was recruited to Southern Research, where he is began working in the lab of Dr. Janet Houghton, and now the lab of Dr. Rebecca Boohaker. Dr. Zhang’s main research focus is to discover novel anti-cancer drugs, especially against colorectal cancer, and perform research on underlying mechanisms of Gli-inhibitor induced DNA damage.